Evaluation of shelf-life of samples of investigational clinical drug formulations, to include parenteral, oral, and other types of dosage forms.
Ended Awarded Last action
- Contract number
- 75N91023F00001
- Awardee
-
Mriglobal UEI HKQHNFKNKL15
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $949,295
Award facts
- Opportunity
-
- DFMC20231003 Solicitation number
- Contract value 100% obligated
- $949,295.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Kansas City, MO 64110, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Exercise an Option | $158,581 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $381,017 | |
| Funding Only Action | $41,424 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $368,273 |
About this award
This is a cost-plus-fixed-fee delivery order contract awarded by the National Cancer Institute, a civilian agency within the Department of Health and Human Services, to Mriglobal, doing business as Midwest Research Institute, a non-profit research organization. The contract is valued at $949,295.00 and will run through January 31, 2026.
The contract is for the evaluation of the shelf-life of samples of investigational clinical drug formulations, including parenteral, oral, and other dosage forms, as well as analytical and stability evaluations of investigational dosage forms and active pharmaceutical ingredients (APIs). This work is part of a larger $146.3 million Indefinite Delivery Contract the organization holds with the National Institute of Allergy and Infectious Diseases for pre-clinical evaluation of infectious disease countermeasures. The contract does not have a small business set-aside designation.
Quick answers
Who was awarded contract 75N91023F00001?
75N91023F00001 was awarded to Mriglobal by National Cancer Institute (National Institutes of Health) on August 1, 2023.
How much is contract 75N91023F00001 worth?
The government has obligated $949,295 on 75N91023F00001.
Is contract 75N91023F00001 an order under another contract?
Yes. 75N91023F00001 is a delivery order under 75N98019D00061, an indefinite delivery contract, on Drug Formulation and Manufacturing Contracts 2019.
Was contract 75N91023F00001 competed?
The extent of competition for 75N91023F00001 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award